Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 16:17:485-494.
doi: 10.2147/CEOR.S503735. eCollection 2025.

Adding Tolvaptan in the Inpatient Treatment for Patients with Heart Failure and Hyponatremia: Budget Impact Analysis in Thailand

Unchalee Permsuwan  1   2 , Krit Leemasawat  3 , Poukwan Arunmanakul  1   2   4
Affiliations

Adding Tolvaptan in the Inpatient Treatment for Patients with Heart Failure and Hyponatremia: Budget Impact Analysis in Thailand

Unchalee Permsuwan et al. Clinicoecon Outcomes Res. .

Abstract

Objective: Tolvaptan is used as an add-on therapy for heart failure (HF) patients with volume overload, particularly those with hyponatremia (HN), but its cost raises concern. This study aimed to estimate the budget impact of adding 30 mg of tolvaptan to standard treatment compared to standard treatment alone in hospitalized HF patients with HN in Thailand.

Methods: A budget impact analysis (BIA) model was developed in accordance with Thai Health Technology Assessment guidelines from the payer's perspective. Epidemiological data on HF in Thailand were used to estimate the target population. Clinical effectiveness data were derived from the EVEREST trial. Cost components included tolvaptan acquisition and HF-related hospitalization costs. Cost data were sourced from the National Health Security Office. The net budget impact (NBI) was calculated as the difference in total budget between standard care with tolvaptan and standard care alone. Deterministic sensitivity analysis was performed to explore the impact of key variables.

Results: The total budget without tolvaptan was 201 million THB (5,802,973 USD), increasing to 221 million THB (6,365,607 USD) with tolvaptan, resulting in an NBI of 19.5 million THB (562,634 USD) or 1117 THB (32 USD) per member. Despite higher drug costs, tolvaptan use reduced hospitalization costs (4.2 million USD vs 5.8 million USD) due to fewer HF hospitalization days and length of stay reduction. A lower tolvaptan dose, reduced HN risk, or a daily cost reduction of at least 25.5% could result in a negative NBI.

Conclusion: Although tolvaptan reduced hospital length of stay, its use at 30 mg daily still led to a positive NBI. These findings are relevant for Thailand and similar healthcare systems considering tolvaptan adoption.

Keywords: budget impact analysis; heart failure; hyponatremia; tolvaptan.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow diagram of budget impact analysis.
Figure 2
Figure 2
Result of deterministic sensitivity analysis ((A) length of stay reduction for tolvaptan treatment, (B) length of stay for heart failure hospitalization).
Figure 3
Figure 3
Result of deterministic sensitivity analysis ((A) risk of hyponatremia, (B) daily cost of tolvaptan).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Njoroge JN, Teerlink JR. Pathophysiology and therapeutic approaches to acute decompensated heart failure. Circ Res. 2021;128(10):1468–1486. doi: 10.1161/CIRCRESAHA.121.318186 - DOI - PMC - PubMed
    1. Miller WL. Fluid volume overload and congestion in heart failure: time to reconsider pathophysiology and how volume is assessed. Circ Heart Fail. 2016;9(8):e002922. doi: 10.1161/CIRCHEARTFAILURE.115.002922 - DOI - PubMed
    1. Rubio-Gracia J, Demissei BG, Ter Maaten JM, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. J Cardiol. 2018;1(258):185–191. - PubMed
    1. Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964–1975. doi: 10.1056/NEJMra1703100 - DOI - PMC - PubMed
    1. Cyr PL, Slawsky KA, Olchanski N, et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. AJHP. 2011;68(4):328–333. doi: 10.2146/ajhp100217 - DOI - PubMed

LinkOut - more resources